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Abstract. The reinforcing and discriminative stimulus 
effects of brotizolam, a benzodiazepine-hypnotic, were 
evaluated in rhesus monkeys. In one experiment, 
separate groups of monkeys (N= 3/group) were trained 
to discriminate pentobarbital (t0 mg/kg, IG) or d-am- 
phetamine (0.56-1.0 mg/kg, IG) from saline, in a dis- 
crete-trials avoidance/escape paradigm. Pentobarbital 
(5.6-10 mg/kg), diazepam (t.0-1.7 mg/kg), and 
brotizolam (0.3-1.7 mg/kg) resulted in 100% drug-lever 
responding in all three pentobarbital-trained monkeys. 
In d-amphetamine-trained monkeys brotizolam ad- 
ministration resulted only in saline-lever responding. In 
another experiment, monkeys were surgically prepared 
with indwelling intravenous catheters and lever pressing 
resulted in an injection of 0.1 mg/kg/injection sodium 
methohexital under a fixed-ratio 10 (FR 10) schedule. 
Pentobarbital (0.010.3 mg/kg/injection) and diazepam 
(0.003-0.10 mg/kg/injection) maintained responding 
above saline control levels when substituted for meth- 
ohexital. Brotizolam (0.001~).01 mg/kg/injection) resul- 
ted in more injections received compared to saline, but 
fewer injections compared to pentobarbital or diazepam. 
Thus, results from the present experiment suggest that 
brotizolam would have pentobarbital-like subjective ef- 
fects. However, the abuse liability of brotizolam may be 
lower than that for diazepam. 
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Brotizolam is a thienotriazolodiazepine hypnotic that 
has been reported to have clinical utility in the treatment 
of insomnia (Vetasco et al. 1981; Mamelak et al. 1983, 
t 989; Roehrs et al. t 983 ; Rickels et al. 1986; Langley and 
Clissold 1988). Brotizolam has a half-life of 3-6 h (cf 
Rickels 1986), compared to diazepam with a half-life 
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after oral administration of between approximately 20 
and 96 h (Mandelli et al. 1978; Rall and Schleifer 1980). 
In a recent review, Langley and Clissold (1985) reported 
that brotizolam was at least as effective as other ben- 
zodiazepines in treating insomnia, and because of its 
intermediate elimination half-life, may have fewer side 
effects. 
In animal studies, brotizolam has been shown to have 
behavioral effects similar to those of diazepam. For ex- 
ample, brotizolam increases rates of food-maintained 
responding that have been suppressed by punishment 
(Ueki et al. 1984), an effect that is characteristic of a 
number of antianxiety drugs (Sepinwall and Cook 1978 ; 
Barrett and Witkin 1990). B6ke-Kuhn et al. (1986) re- 
ported that brotizolam increased punished responding of 
rats to a similar degree as diazepam and was equally 
effective as an anticonvulsant and antiaggressive agent. 
In addition, these investigators demonstrated that motor 
coordination was not impaired by brotizolam doses that 
were behaviorally active, suggesting that the differences 
between effective anxiolytic doses and doses with muscle 
relaxant effects may make brotizolam preferable to 
diazepam in the treatment of anxiety (B6ke-Kuhn et al. 
1986; Lehr et al. 1986). 
Drug discrimination and drug self-administration 
procedures have been shown to be predictive of the abuse 
liability of drugs (see Johanson et al. 1987; Woolverton 
and Nader 1990). In the present study, the behavioral 
effects of brotizolam using these procedures were com- 
pared to those of two other sedative-hypnotics, diazepam 
and pentobarbital. Previous research has found that 
there is considerable cross-generalization among seda- 
tive/hypnotics of several chemical classes (Ator and Grif- 
fiths 1989). For example, when animals are trained to 
discriminate pentobarbitat from saline, responding 
generalizes from the pentobarbital stimulus to other bar- 
biturates and benzodiazepines. In the present study, one 
group of rhesus monkeys was trained to discriminate 
pentobarbital from saline, in a discrete-trials avoidance 
and escape paradigm, similar to the procedure described 
by Holtzman (1982). A second group was trained to 
discriminate amphetamine from saline. The discrimina- 
tive stimulus effects of brotizolam were studied in both 
groups. To provide comparison data, diazepam was also 
tested in pentobarbital-trained monkeys. 
A second series of experiments assessed whether 
brotizolam could function as a positive reinforcer. Most 
drugs that are abused by humans are self-administered 
by nonhuman animals (Griffiths et al. 1980). In general, 
injections of benzodiazepines can maintain responding of 
animals, although drugs of this class are less efficacious 
when compared to drugs such as cocaine and pentobar- 
bital (cf Griffiths et al. 1985). The present study examined 
whether brotizolam could maintain responding when 
substituted for the ultra-short acting barbiturate sodium 
methohexital. In addition, the rate of responding main- 
tained by brotizolam was compared with response rates 
maintained by diazepam and pentobarbital. 
Materials and methods 
Experiment 1 : Drug discrimination 
Subjects. Six adult rhesus monkeys (Macaca mulatta), two female 
(M 7976, M-8515) and four male (M-8236, M-8106, M-7739 and 
M 7737), weighing between 7.0 and 13 kg served as subjects. All 
monkeys had received other test drugs prior to the start of the 
present study. Monkeys were individually housed in stainless steel 
cages with water available continuously. Supplemental feeding con- 
sisted of 100-150 g Purina Monkey Chow daily, 30 min after each 
session, and a chewable vitamin tablet 3 days/week. 
Apparatus. During experimental sessions monkeys were seated in a 
restraining chair (Plas-Labs, Lansing, MI) and placed in a wooden 
cubicle (175 cm high x 85 cm wide x 65 cm deep) containing two 
response levers mounted 110 cm above the floor and a 40 W white 
houselight mounted on the ceiling. Above each lever were two sets 
of white jewel lights. The monkey's feet were placed into shoes, the 
bottoms of which were fitted with brass plates through which elec- 
tric shocks could be delivered. Programming and recording of  
experimental events were accomplished by an Aim 65 microcom- 
puter located in an adjacent room. 
Procedure. All monkeys had previously been trained in a discrete- 
trials shock avoidance/escape paradigm to discriminate either pen- 
tobarbital or d~amphetamine from. saline (N= 3/group). One hour 
after an intragastric infusion (via nasogastric tube) of the training 
drug (0.561.0 mg/kg d-amphetamine or 10 mg/kg pentobarbital) 
or saline, the houselight and lever lights were illuminated (trial) and 
a response on one lever (the correct lever) avoided electric shock and 
extinguished the lights. To prevent adventitious reinforcement of 
response chains, responding on the incorrect lever started a 2-s 
change-over-delay during which correct responses had no program- 
med consequence. If a correct response was not made within 5 s 
following onset of the lights, electric shock (250 ms duration, 
7.0 mA intensity) was delivered every 2 s until a correct response 
was made (escape) or until two shocks had been delivered. Trials 
were separated by a 30-s timeout. Sessions began with a 5 rain 
timeout and ended after 30 trials or 20 min, whichever came first. 
In addition, sessions were terminated early if two shocks occurred 
(i.e., no avoidance or escape responding) in two consecutive trials. 
The correct lever was determined by the infusion that was adminis- 
tered before the session. For three monkeys the right lever was 
correct after drug infusions and the left lever was correct after saline 
infusions. This condition was reversed for the other three monkeys. 
Training sessions were conducted 5 days a week according to 
the following schedule: SDDSS, DSSDD, where S denotes saline 
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trials and D indicates sessions preceded by drug administration. 
Training of the drug-saline discrimination continued until a correct 
response was made on the first trial and on at least 90 % of the total 
trials on at least seven out of eight consecutive sessions, at which 
point testing began. A test session was one in which different doses 
of the training drug or a drug other than the training drug was 
administered. Two different weekly sequences alternated drug, sa- 
line and test sessions so that the first test session each week was 
preceded by two training sessions, one with saline and one with drug 
pretreatment and the second test session of  the week was preceded 
by either vehicle or drug pretreatment (i.e., SDTST, DSTDT, where 
T denotes a test session). In the event that the criterion for stimulus 
control was not met during the training sessions, the training 
sequence continued. Test sessions were similar to training sessions 
except that a response on either lever prevented shock delivery. 
Prior to testing brotizolam, a pentobarbital (1.0.10 mg/kg) or 
d-amphetamine (0.03-1.0 mg/kg) dose-response curve was deter- 
mined, with doses administered in random order. Initial test doses 
of brotizolam were examined in an ascending order from 0.1 mg/kg 
to doses that either resulted in at least 90% drug-appropriate re- 
sponding or increased response latency to the point that avoidance 
responding was disrupted. The three highest doses, in addition to 
the drug vehicle, were tested at least twice in each monkey. 
Pentobarbital-trained monkeys were also tested with diazepam 
(0.3-1.7 mg/kg). 
Experiment 2: Self-administration 
Subjects. Seven rhesus monkeys (5.14.1 kg), two of which were 
males (El and 1708), served as subjects. Monkeys were fed 100-150 
g high protein Purina Monkey Chow twice daily, at least 30 min 
prior to initiation of each of two daily self-administration sessions. 
Silicone catheters were surgically implanted in a major vein (jug- 
ular, femoral or brachial) in each monkey using 10 mg/kg IM 
ketamine and 15 mg/kg IV pentobarbital as anesthetics. The cath- 
eter passed subcutaneously from the site of implantation to the 
mid-scapular region, where it exited the monkey and continued, 
through a hollow restraining arm, to the outside rear of the cage. 
All but one subject (600) had previous experience self-administering 
either cocaine or codeine. Two monkeys (1708, 833), in addition, 
had previously been exposed to schedules in which responding 
terminated drug infusions. 
Apparatus. The restraint and catheter protection device has been 
described in detail by Deneau et al. (1969). Monkeys were individu- 
ally housed in stainless steel cages, measuring 83.3 x 76.2 x 91.4 cm 
deep. Each monkey wore a tubular stainless steel harness that 
protected the exit site of the catheter and allowed relatively unre- 
stricted movement within the chamber. Some monkeys wore a 
Teflon cloth jacket (Alice King Chatam Medical Arts, Los Angeles, 
CA) to provided further catheter protection. The harness was con- 
nected to a tubular, jointed arm that carried the catheter to the back 
of the cage where it joined tubing passing through a roller infusion 
pump (Watson and Marlow Co., Model M H R K  55; Falmouth, 
UK). 
A 15.4 cm square stimulus panel was located on the side of each 
cage, approximately 10 cm from the front and 19 em from the 
bottom of the cage. Across the top of the stimulus panel were three 
circles, 2.5 cm in diameter and 2.5 cm apart, covered with translu- 
cent plastic and capable of being transilluminated by 5 W colored 
bulbs. The two side lights could be illuminated red and the center 
light could be illuminated green. Below each of the two red stimulus 
lights was a response lever (Model 121 07; BRS-LVE, Beltsville, 
MD), capable of being operated by 10-15 g force. Experimental 
control was provided by individual IBM PCjr computers located in 
an adjoining room. BASIC software was used to control experi- 
mental procedures. 
Procedure. Monkeys were adapted to restraining arms for a week 
or more; then an intravenous catheter was implanted and they were 
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given the opportunity to respond and receive drug. The beginning 
of a session was signalled by the illumination of  a red light above 
one of two levers in each monkey's cage and initially each response 
produced a 5-s injection of 0.1 mg/kg sodium methohexital. The 
number of responses required to deliver drug was gradually in- 
creased to 10 responses (fixed-ratio 10; FR 10), with each injection 
followed by a 10-s timeout during which alI stimulus lights were 
extinguished and responding had no programmed consequence. 
During an injection, the red lever light was extinguished and the 
green center light was illuminated. Experimental sessions were lim- 
ited to 130 min or 200 infusions; however, no monkey ever received 
200 injections of  methohexital. Two sessions were scheduled each 
day, separated by at least 4 h. During approximately one-half of  the 
sessions saline was made available. When there was a clear dif- 
ference in the number of injections of saline and methohexital, test 
compounds were substituted during single sessions, no more fre- 
quently than once every fourth session. Dose-response curves were 
determined for methohexital, pentobarbital, brotizolam and 
diazepam. Each dose was tested at least twice in three monkeys. 
Drug administration. For the drug discrimination experiment, so- 
dium pentobarbital (Sigma Chemical Co., St Louis, MO) and d- 
amphetamine (National Institute on Drug Abuse, Rockville, MD) 
were dissolved in saline, while brotizolam (obtained from the Com- 
mittee on Problems of Drug Dependence) and diazepam (Hoff- 
mann-La Roche, Nutley, N J) were dissolved in an emulphor: 95% 
ethanol (1 : 1) vehicle. Approximately 1-11 ml of drug was adminis- 
tered, followed by a 1 ml saline flush. For self-administration stu- 
dies, sodium methohexital (Eli Lilly, Indianapolis, IN) was dissol- 
ved in sterile water, diazepam was prepared in a solution containing 
commercial diluent (Hoffmann-La Roche) and sterile water, and 
brotizolam was dissolved in a Tween 80:95% ethanol (1:1) vehicle 
and diluted with sterile water. 
Results 
Drug discrimination 
In monkeys trained to discriminate pentobarbital from 
saline, pentobarbital (3.0-10 mg/kg) produced a dose- 
related increase in drug-appropriate responding (Fig. 1 ; 
left panel), with 100% drug-lever responding following 
administration of the training dose (10 mg/kg) in all 
monkeys. For two monkeys, doses lower than the train- 
ing dose occasioned only saline-lever responding, while 
administration of 5.6 mg/kg resulted in 100% pentobar- 
bital-lever responding in M-8106 (Fig. 1). There was also 
a dose-related increase in response latency. Although 
response latency increased relative to saline controls, 
subjects rarely received shocks following pentobarbital. 
Administration of diazepam (0.3-1.7 mg/kg) also 
resulted in a dose-related increase in pentobarbital- 
appropriate responding (Fig. 1; middle panel). For all 
subjects, diazepam substituted for pentobarbital at doses 
that increased response latency relative to saline controls. 
These increases in response latency were similar to the 
effects produced by the training dose of pentobarbital. 
Brotizolam (0.03-3.0 mg/kg) occasioned 100% pen- 
tobarbital-lever responding in all three subjects tested 
(Fig. 1; right panel). In all pentobarbital-trained mon- 
keys, initial administration of an intermediate dose of 
brotizolam resulted in 100% pentobarbital-appropriate 
responding. However, when these doses were retested, 
only partial substitution was observed. There was in- 
dividual variability in the sensitivity to brotizolam, with 
100% drug-lever responding occurring in each monkey 
between doses of 0.3 and 3.0 mg/kg. Administration of 
the drug vehicle occasioned only saline-appropriate re- 
sponding (data not shown). Brotizolam increased re- 
sponse latency in a dose-related manner. Doses of 
brotizolam that completely substituted for pentobarbital 
increased response latency relative to saline control. For 
M-7976 and M-8106, the highest dose of brotizolam 
disrupted avoidance responding; this dose was only test- 
ed once, since these monkeys were too sedated to be 
chaired following the second administration. 
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Fig. 1. Eft?cts of pentobarbitat, 
diazepam and brotizolam in rhesus 
monkeys trained to discriminate t0 
mg/kg pentobarbital from saline. The 
top panel represents the percentage of  
total responses during test sessions in 
which pentobarbital-lever responding 
occurred, while the lower panel depicts 
the average response latency per trial. 
Each point is the average of two to 
three determinations, except the highest 
dose of brotizolam in M-7976 and 
M 8106, which was only tested once. 
The unconnected symbols at the far left 
represent the average of Thursday 
saline (S) sessions. Each control point 
is the mean of at least ten sessions. 
Vertical lines represent the range of 
effects. • M-8236; © M-7976; 
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Fig. 2. Number of injections 
self-administered as a function of dose 
for methohexital, pentobarbital, 
diazepam and brotizolam. Each drug 
was tested in three monkeys and filled 
symbols represent the average. 
Responding was maintained under a 
fixed-ratio 10 schedule and session 
length was 130 rain. Pentobarbital, 
diazepam and brotizolam were 
substituted for 0.1 mg/kg/injection 
methohexital. Each point is the mean 
of at least two determinations, except 
0.03 mg/kg/injection methohexital for 
monkey 600 and 0.3 mg/kg/injection 
methohexital for subject 833, which 
were determined once. Unconnected 
points at the left represent the number 
of injections received when saline or 
0.1 mg/kg/injection methohexital was 
available for injection. © 833; A 699; 
[] 583C; V600; ® 1708; AE1; NCo; 
• average 
The training dose of d-amphetamine was 0.56 mg/kg 
for M-7737 and M-7739 and 1.0 mg/kg for M-8515. 
During test sessions, the training dose and higher doses 
of amphetamine (0.56-1.7 mg/kg) resulted in 100% drug- 
lever responding (data not shown). These doses also 
increased response latency. In two monkeys (M-7737 
and M-8515), a dose lower than the training dose com- 
pletely substituted for amphetamine, whereas in all sub- 
jects the lowest dose tested (0.1 mg/kg) and saline result- 
ed in 0% drug-lever responding. 
Administration of brotizolam (0. t-1.0 mg/kg) result- 
ed in only saline-lever responding in all amphetamine- 
trained monkeys (data not shown). Response latency 
increased in a dose-dependent manner in all subjects. For 
M-7739, initial administration of brotizolam 0.3 mg/kg 
had no effect on response latency, while 1.0 mg/kg in- 
creased response latency and disrupted avoidance re- 
sponding. When 0.3 mg/kg was retested several months 
after 1.0 mg/kg, responding was completely eliminated. 
For the other two monkeys, avoidance responding was 
disrupted at doses of 0.1 (M-7737) and 0.56 mg/kg 
(M 8515). 
Self -admin&tration 
Methohexital injections maintained responding in all 
subjects tested (Fig. 2). An inverted "U" shaped function 
was observed in all three monkeys, with the highest 
number of injections (97 135 injections) occurring at a 
dose of 0.1 mg/kg/injection. When saline was made avail- 
able following each FR 10, the number of injections 
received per session decreased to less than 30 for all three 
monkeys. 
When pentobarbital was available a greater number 
of injections were received compared to saline in all three 
subjects tested (Fig. 2). At the most effective dose of 
pentobarbital (0.03-0.10 mg/kg/injection), the number of 
injections received was similar to that observed when 
0.10 mg/kg methohexital was available. Diazepam 
(0.01-0.10 mg/kg/injection) also consistently maintained 
responding when substituted for methohexital. For two 
monkeys, the most injections received occurred when 
0.03 mg/kg/injection diazepam was available, while 0.01 
mg/kg/injection resulted in the largest number of 
diazepam injections in 583C (Fig. 2). Although diazepam 
was readily self-administered, the average number of 
injections received per session at optimal doses was lower 
than occurred at 0.1 mg/kg/injection methohexital. 
For all subjects, when brotizolam (0.0001-0.03 mg/ 
kg) was available, more injections were received than 
when saline was available (Fig. 2). The number of injec- 
tions received as a function of dose represented an inver- 
ted "U" shaped curve, with the most injections delivered 
when 0.001 mg/kg/injection was available. Total number 
of injections decreased from an average of 126 when 0.1 
mg/kg/injection methohexital was available, to 42 injec- 
tions when 0.001 mg/kg/injection brotizolam was avail- 
able. Of the drugs studied in this experiment, brotizolam 
was the most potent. However, compared to the other 
drugs tested, brotizolam resulted in fewer number of 
injections received per session. 
Discussion 
The reinforcing and discriminative stimulus effects of the 
sedative/hypnotic benzodiazepine brotizolam were 
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evaluated in rhesus monkeys and compared to diazepam 
and pentobarbital. In the drug discrimination study, 
brotizolam and diazepam completely substituted for pen- 
tobarbital in all monkeys tested. These findings are con- 
sistent with previous results showing that benzodiaze- 
pines can substitute for pentobarbital (Herling et at. 
1980; Winger and Herling 1982; Ator and Griffiths 
1983). Thus, results from the present study suggest that 
the subjective effects of brotizolam would be similar to 
those of other CNS depressants, such as pentobarbital 
and diazepam. On the other hand, when the discrimina- 
tive stimulus effects of brotizolam were studied in mon- 
keys trained to discriminate d-amphetamine from saline, 
no drug-lever responding was observed. Others have 
reported that administration of direct and indirect dopa- 
mine agonists, including dopamine reuptake blockers, 
can substitute for the amphetamine stimulus (Nielsen 
and Scheel-Kr/iger 1988). In that light, the present results 
in which brotizolam occasioned only saline-lever res- 
ponding in amphetamine-trained monkeys are not sur- 
prising, since benzodiazepines have been shown to de- 
crease dopamine turnover in brain (Corrodi et al. 1971 ; 
Ishiko et al. 1983). 
When substituted for the maximum rate-maintaining 
dose ofmethohexital, one or more doses ofpentobarbital 
maintained behavior to nearly the same extent as metho- 
hexital. Diazepam-maintained responding approxi- 
mated that seen with pentobarbital and methohexital. In 
contrast, number of injections received when brotizolam 
was available was only slightly higher compared to sa- 
line. The finding that diazepam was a positive reinforcer 
in these monkeys was somewhat surprising, since 
diazepam has been found to maintain considerably less 
behavior than barbiturates in similar circumstances 
(Griffiths et aI. 1985; Ator and Griffiths 1987). One 
variable that may have contributed to the clear reinforc- 
ing effects of diazepam in the present experimental para- 
digm was the fact that a sedative/hypnotic drug, metho- 
hexital, rather than a drug from another pharmacologi- 
cal class was used as the standard drug for self- 
administration. Diazepam has been shown to maintain 
higher rates of responding when it was substituted on a 
pentobarbital baseline than when it was substituted on 
a cocaine baseline (Bergman and Johanson I985). In 
addition, the fact that a low value fixed-ratio and a low 
value timeout were used to maintain the behavior may 
have contributed to diazepam's reinforcing effects. It has 
been shown by other investigators (Goldberg et al. 1971 ; 
C.E. Johanson, personal communication) that sedative/ 
hypnotics do not maintain behavior well when higher 
fixed-ratio values are used to maintain responding. Like- 
wise, sedative/hypnotics are typically self-administered in 
a burst pattern (e.g., Winger et al. 1975), which is disrupt- 
ed if long timeout values are programmed after each 
injection. If the burst pattern is allowed to develop by 
programming relatively short timeouts after each injec- 
tion, self-administration of sedative/hypnotics may be 
more likely to occur. 
Possible explanations for the reinforcing effects of 
diazepam do not explain the low number of injections 
received when brotizolam was available under these cir- 
cumstances. When two drugs have similar discriminative 
stimulus effects, but different reinforcing effects, it is 
sometimes the case, especially with opiates, that they 
differ in their pharmacokinetics (Bertatmio et al. 1990). 
Drugs with rapid onsets of action and short durations of 
action are more likely to maintain behavior, given that 
they have subjective effects in common with other rein- 
forcing drugs, than are drugs with slow onsets and long 
durations of action. Brotizolam's onset of action follow- 
ing intravenous administration in monkeys has not been 
reported, but there is no a priori reason to think that it 
would be delayed relative to diazepam. Its duration of 
action is considerably shorter than that of diazepam, so 
that neither of these effects can easily account for the low 
rates of responding maintained by brotizolam. It is un- 
likely that general pharmacodynamic differences between 
triazolobenzodiazepines and more typical benzodiazepi- 
nes can explain the differences observed here, since the 
triazolodiazepines triazolam and midazolam, when de- 
livered intravenously and contingently to baboons, 
maintained higher rates of behavior than did diazepam 
(Griffiths et al. 1981, 1985). Thus, the resolution of this 
anomalous difference between the reinforcing effects of 
diazepam and brotizolam lies in further experiments on 
these two compounds. 
Abuse liability of a compound is defined, at least in 
part, in terms of a drug's capacity to function as a posi- 
tive reinforcer (cfWoods 1983 ; Woods et al. 1987). Based 
on the present results involving drug self-administration, 
it appears that the abuse liability of brotizolam is lower 
compared to diazepam, However, it should be em- 
phasized that brotizolam would be predicted to have 
subjective effects in common with barbiturates, a class of 
drugs with established abuse liability. Abuse liability 
may also be assessed by the presence and severity of 
withdrawal signs following chronic administration. 
Stockhaus and Bechtel (1986) compared the physical 
dependence capacity of brotizolam with diazepam in 
rhesus monkeys. In that study both brotizolam and 
diazepam were administered by nasogastric tubes three 
times daily for 61 consecutive days. Tolerance did not 
develop to either drug's effects on motor coordination. 
After discontinuation of daily drug administration, with- 
drawal signs for brotizolam were evident on the first day, 
while the abstinence syndrome was highest on days 2-5 
following diazepam discontinuation. Most withdrawal 
symptoms following chronic brotizolam had faded by 
day 2. The doses used to induce physical dependence in 
this study were 500- and 96-times the therapeutic human 
dose for brotizolam and diazepam, respectively. Stock- 
haus and Bechtel's (1986) results suggest that withdrawal 
from daily brotizotam treatment would produce less be- 
havioral disruption than withdrawal from diazepam. 
These data, taken together with the results from the 
present self-administration study, suggest that the abuse 
liability of brotizolam may be lower than that for 
diazepam. 
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